In addition, CYH33 is a highly selective oral PI3Kα inhibitor, with an objective response rate (ORR) of 14.3% in treating PIK3CA-mutated solid tumors, including HNSCC (NCT03544905) [31]. The gene discussed is PIK3CA; the disease is head and neck squamous cell carcinoma.